Citations

Clear

10 citation(s) found for "Chawla, Yogesh".

Role of ADAR1 in regulating IFN and TNF mediated responses 2260792
Ghale, Romina , Chawla, Yogesh, Krogman, Erica, Ting, Adrian , Krogman, Erica N., Ting, Adrian

Mayo Clinic

The Journal of Immunology | July 28, 2026 | Volume: 215 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkag141.984 Get It

Abstract Introduction Immunotherapy has achieved remarkable success in hematologic malignancies, but its efficacy in solid tumors remains limited due to tumor heterogeneity, immune suppression within the tumor microenvironment, and inefficient T cell infiltration. I hypothesize that enhancing tumor cell sensitivity to cytokine-mediated killing can potentiate paracrine killing, in which T cell—derived cytokines induce tumor cell death even without direct cell—cell contact. This mechanism can overcome antigen heterogeneity and limited T cell penetration, broadening the therapeutic reach of immunotherapy. Methods I propose targeting ADAR1, an RNA-editing enzyme that suppresses innate immune activation, to enhance paracrine killing. Loss of ADAR1 leads to dsRNA accumulation and activation of PKR, MDA5, and RIG-I, sensitizing tumor cells to T cell—derived cytokines such as IFNγ and TNF. To test this, I performed in vitro paracrine killing co-culture assays using T cells from healthy donor PBMCs, antigen-positive tumor targets, and GFP-labeled antigen-negative ADAR1KO tumor targets. GFP signal loss in ADAR1KO cells will indicate enhanced paracrine killing independent of antigen recognition. Results My data show that ADAR1 inhibition sensitizes tumor cells to cytokine-mediated cytotoxicity, though how dsRNA sensor and cytokine receptor signaling intersect remains unclear. Supernatant from antigen-positive T cell—tumor co-cultures induced cell death in ADAR1KO but not WT tumor targets, indicating selective cytokine sensitivity. Consistently, Western blot analysis revealed increased cleaved Caspase-3 and PARP in ADAR1KO cells. The paracrine killing assay is ongoing. Conclusion This study aims to elucidate the interplay between dsRNA sensing and cytokine signaling in the absence of ADAR1 and to define how this crosstalk shapes the efficacy of paracrine killing in solid tumors. These insights could inform new therapeutic strategies to enhance the potency of immunotherapy against resistant and heterogeneous solid tumors. Funding Source n/a Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
Loss of the kinases TBK1 and IKKε sensitizes target cancer cells to T cell killing through an IFN-γ–mediated inflammatory death program
Sun, N , Carr, Allison R. , Krogman, Erica N., Chawla, Yogesh , Zhong, Jun , Guttormson, Matthew C. , Chan, Mark , Hsu, Michelle A. , Dong, Haidong , Patel, Roosheel S. , Pandey, Akhilesh , Rogers, Laura M. , Ting, Adrian T. , Sun, Nicholas D , Bogunovic, Dusan , Pandey, Akhilesh , Dong, Haidong , Ting, Adrian T , Zhong, Jun , Rogers, Laura M , Chawla, Yogesh

Mayo Clinic

Science Signaling | July 7, 2026 | Volume: 19 | Issue: 945 | Pages: No page available

10.1126/scisignal.adz7366 | PMID 42412915 Get It

Cytotoxic T cells produce the cytokine interferon-γ (IFN-γ). We sought to determine whether IFN-γ directly kills target cells and found that T cells used IFN-γ to kill murine melanoma cells lacking the kinases TBK1 and IKKε. In the absence of both kinases, IFN-γ induced the production of TNF receptor 1 (TNFR1) and the sensor Z-DNA binding protein 1 (ZBP1) in the tumor cells to stimulate receptor-interacting protein kinase 1 (RIPK1)–dependent apoptosis in a cell-autonomous manner. IFN-γ also enhanced the activation of nuclear factor κB (NF-κB) signaling in a TNFR1-dependent manner in cells deficient in both TBK1 and IKKε. Because IFN-γ–induced apoptosis occurred in a transcription-dependent manner with slow kinetics, STAT1 and NF-κB cooperated to activate the expression of inflammatory genes in the dying cells. Thus, IFN-γ–induced cell death was accompanied by an inflammatory signature in the absence of TBK1 and IKKε. TBK1 and IKKε not only mediated the induction of type I IFN but also inhibited RIPK1-dependent death and NF-κB–dependent inflammation. Therefore, we propose that these kinases may have gained these intertwined functions so that cells infected by pathogens that produce antagonists of TBK1 and IKKε are eliminated by IFN-γ–secreting T cells in an inflammatory manner to compensate for the inhibition of type I IFN production.
Metabolic Heterogeneity and Niche Rewiring in Plasma Cells are Associated with Progression from MGUS to Multiple Myeloma
Walch, A, Zhang, Guoxing, Sun, Na , Chawla, Yogesh , Jevremovic, Dragan, Taro, Hitosugi, Kumar, Shaji, Gonsalves, Wilson, Jevremović, Dragan , Gonsalves, Wilson I. , Jevremovic, Dragan , Kumar, Shaji K , Gonsalves, Wilson , Sun, Na, Chawla, Yogesh , Taro, Hitosugi, Kumar, Shaji , Walch, Axel

Mayo Clinic

No container title available | February 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8795835/v1 | PMID 41756448 Get It

Abstract Progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) is driven by coordinated metabolic reprogramming within clonal plasma cells and the bone marrow microenvironment. We applied high-resolution MALDI–FT-ICR mass spectrometry imaging (MSI) to archived FFPE bone-marrow biopsies, integrated with matched bone marrow plasma metabolomics, to map spatial and systemic metabolic alterations. Spatial clustering delineated plasma-cell–rich niches, while Hill-based diversity and β-diversity metrics quantified intra- and inter-compartment heterogeneity. MM niches exhibited elevated 3-hydroxykynurenine, rewired tryptophan–kynurenine flux, and increased nucleotide and bioactive lipid metabolism associated with proliferation. Notably, some MGUS-like samples displayed MM-like metabolic niches undetectable in bone marrow plasma alone, underscoring spatial heterogeneity. Cross-compartment integration revealed conserved metabolic signatures and systemic redistribution of key metabolites, consistent with ecological reorganization and niche divergence during progression. These findings establish spatial metabolomics of biopsies as a framework to dissect intramedullary metabolic heterogeneity and enable metabolite-based risk stratification in plasma-cell disorders.
Altered bone marrow (BM) plasma amino acid (AA) composition reflects microenvironmental remodeling in patients with multiple myeloma (MM) compared to monoclonal gammopathy of unknown significance (MGUS)
Egan, Michael, Chawla, Yogesh, Dey, Puja, Jevremovic, Dragan, Hitosugi, Taro, Kumar, Shaji, Gonsalves, Wilson, Egan, Michael, Chawla, Yogesh, Dey, Puja, Jevremovic, Dragan, Hitosugi, Taro, Kumar, Shaji, Gonsalves, Wilson

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 2149-2149

10.1182/blood-2025-2149 Get It

Abstract Altered Bone Marrow (BM) Plasma Amino Acid (AA) Composition Reflects Microenvironmental Remodeling in Patients with Multiple Myeloma (MM) compared to Monoclonal Gammopathy of Unknown Significance (MGUS) Michael Egan, Yogesh Chawla, Puja Dey, Dragan Jevremovic, Taro Hitosugi, Shaji Kumar and Wilson Gonsalves BACKGROUND: MYC overexpression, a hallmark of progression from MGUS to MM, drives metabolic reprogramming, including enhanced AA uptake and utilization. However, the contribution of AAs to disease progression from MGUS to MM remains poorly defined. In this study, we comprehensively profiled AA levels in the BM plasma of MGUS and MM patients to determine whether shifts in the availability of specific AAs reflect microenvironmental remodeling and evolving metabolic demands of malignant plasma cells (PCs). METHODS: AA profiles of BM plasma samples—reflective of the BM microenvironment—from two different cohorts of patients with either MGUS or MM (Cohort #1: 49 MGUS and 50 newly diagnosed MM (NDMM) and Cohort #2: 50 MGUS and 64 NDMM) were acquired using liquid chromatography (LC) coupled with tandem mass spectrometry (MS). Individual AA were quantified by MS using single-point quantification with isotopically labeled internal standards of AAs. Individual relative and quantitative AA data were analyzed for differences between the groups using the parametric t-test, and significance was defined as p < 0.05. We utilized a Pearson correlation coefficient method to determine the association of the percentage of clonal PCs in the BM to the levels of the AAs. The areas under the curve (AUC) of receiver operating characteristic (ROC) analyses were created on the web-based tool MetaboAnalyst 6.0 to determine the ability of quantitative AA levels to be utilized as a model to distinguish MGUS vs. MM. RESULTS: In BM plasma samples from cohort #1, using a global untargeted metabolite profiling, we identified 28 AAs and their metabolites out of the 1,089 known metabolites detected. A targeted quantification of these AAs was performed in the same samples to validate any observed differences between the groups. Both aspartate and glycine were found to be more abundant in NDMM compared to MGUS in both untargeted and targeted assays. In contrast,12 AAs (branched chain AAs: valine, leucine and isoleucine, aromatic AAs: tryptophan, kynurenine, tyrosine and phenylalanine; essential AAs: threonine and lysine; non-essential AAs: ornithine, citrulline and asparagine) were found to be less abundant in NDMM compared to MGUS. We then validated the presence of these differences using targeted quantification of AAs in the BM plasma samples from cohort #2. Aspartate was the only AA consistently found to be present at higher levels in NDMM vs. MGUS. Whereas, 8 AAs—threonine, valine, citrulline, tyrosine, tryptophan, isoleucine, phenylalanine, and kynurenine—were consistently lower in NDMM vs. MGUS. We observed a statistically significant positive correlation between the concentration of aspartate and the percentage of clonal PCs present in the BM (r = 0.56). In contrast, there were statistically significant negative correlations between the concentrations of all 8 AAs consistently lower in NDMM vs. MGUS and the percentage of clonal PCs in the BM: threonine (r = -0.41), valine (r = -0.35), citrulline (r = -0.37), tyrosine (r = -0.28), tryptophan (r = -0.31), isoleucine (r = -0.21), phenylalanine (r = -0.19), and kynurenine (r = -0.19). Using only the quantitative concentrations of the 9 AAs that were significantly different between NDMM and MGUS across both patient cohorts, we performed ROC analyses to develop predictive models distinguishing NDMM from MGUS. In cohort #1, the models yielded AUC values ranging from 0.738 to 0.785, while in cohort #2, AUC values ranged from 0.798 to 0.835, depending on the number of AAs included in the model. CONCLUSIONS: Several AAs are present at significantly different levels in the BM plasma of patients with NDMM compared to MGUS. These findings support the emerging role of AA availability, across a diverse set of AAs, in the pathogenesis and progression of MGUS to MM. Future studies are warranted to validate these observations and to determine whether alterations in the BM AA landscape can be leveraged for diagnostic or therapeutic strategies.
Role of ADAR1 in regulating Interferon-mediated responses 3255
Ghale, Romina, Chawla, Yogesh, Krogman, Erica, Ting, Adrian, Ghale, Romina, Chawla, Yogesh, Krogman, Erica, Ting, Adrian

Mayo Clinic

The Journal of Immunology | November 21, 2025 | Volume: 214 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkaf283.1073 Get It

Abstract Description CAR-T cell therapy has shown remarkable success in treating hematologic cancers; however, its efficacy in solid tumors remains limited, partly due to tumor heterogeneity, immune suppression within the tumor microenvironment, and inefficient CAR-T cell infiltration. I hypothesize that increasing the sensitivity of tumor cells to cytokine-mediated killing could enhance the therapeutic impact of CAR-T cells in solid tumors. I propose that targeting Adenosine Deaminases Acting on RNA 1 (ADAR1), an enzyme that edits double-stranded RNA (dsRNA) to prevent immune activation, may be one such strategy. ADAR1 balances inflammation by preventing the overactivation of dsRNA sensors such as PKR, MDA5, and RIG-I. However, in the absence of ADAR1, accumulating dsRNA structures will trigger these dsRNA sensors and alter the tumor cell intrinsic response to T cell-derived cytokines, such as IFNγ and TNF. My data provide evidence that inhibition of ADAR1 in tumor cells sensitize them to killing by cytokines, but it remains unclear how signaling from dsRNA sensors crosstalk with those from cytokine receptors to regulate cell survival or death. My study aims to elucidate the interplay between these different signaling pathways in the absence of ADAR1, and how this interplay determines the efficacy of CAR-T cells against solid tumors. My experimental observations could provide insights into novel therapeutic strategies to improve CAR-T cell potency against resistant tumor types. Funding Sources Mayo Clinic Cancer Center Fellowship Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
Single-Cell Spatial Proteomic Characterization of Clonal Plasma Cell and Immune Cell Metabolism within the Bone Marrow Microenvironment in High-Risk Smoldering Multiple Myeloma and Its Association with Progression to Multiple Myeloma
Geyer, Susan, Whitaker, Kaitlyn, Kumar, Shaji, Hitosugi, Taro , Soekojo, Cinnie Yentia , Guzman, Emmanuel Contreras , Whitaker, Kaitlyn, Kumar, Shaji , Rajkumar, S. Vincent , Cook, Joselle , Chawla, Yogesh, Buadi, Francis K. , Dispenzieri, Angela , Binder, Moritz , Fonseca, Rafaël , Jevremović, Dragan , Gonsalves, Wilson I. , Villasboas, José C.

Mayo Clinic

Blood | December 6, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 1880-1880

10.1182/blood-2024-207440 Get It

Introduction The tumor ecosystem in multiple myeloma (MM) involves complex interactions among various cell types, including clonal plasma cells (PCs) and immune cells. Previous research has indicated that the bone marrow (BM) microenvironment's metabolite and lipid profiles differ between MM patients and those with precursor conditions. This study aims to explore if differences in cell composition, metabolic phenotype of clonal PCs, and the spatial organization of various cell types are linked to the early versus late progression of high-risk smoldering MM (SMM) to MM. Methods We identified high-risk SMM patients using the IMWG 20-2-20 criteria, focusing on early progressors (EP), who progressed to MM within one year, and later progressors (LP), who progressed after more than four years. Using a high-dimensional single-cell spatial imaging platform, CODEX (CO-Detection by indEXing), we identified clonal PCs and immune cell types as well as their metabolic phenotypes at the single-cell level, in paired FFPE BM samples at SMM diagnosis and at the time of progression to MM. Our validated panel included markers such as CD3e, CD4, CD8, CD14, CD20, CD31, CD38, CD45, CD66a, CD68, CD138, HLA-DR, ASCT2, pNRF2, GLUT1, LDHA, ATPA5, CPT1A, and Citrate synthase. We employed single-cell segmentation, artifact cleanup, signal thresholding, and spatial analysis. Repeated measure models accommodated multiple regions of interest (ROIs) per patient and accounted for potential intrapatient correlation, while Poisson models estimated incidence rate ratios (RR) of cell types. Spatial statistical models evaluated cell type segregation and integration at the time of SMM diagnosis. Results Single cell events were acquired from 6 unique SMM patients who had paired FFPE BM samples from the time of their SMM diagnosis and at the time of their progression to MM. There were 3 EP SMM patients (Time to Progression (TTP):8, 8, 10 mos) and 3 LP SMM patients (TTP: 51, 58, 117 mos). The median number of single cell events identified per patient slide sample was 104,390 (Range: 24,357 - 314,877). We identified 8 main cell types: PCs, CD4+ T-cells, CD8+ T-cells, B-cells, granulocytes, Monocyte/Macrophages and two groups of other immune cells. The PCs and the remainder of the non-PCs were further classified based on the expression of the following metabolic markers: ASCT2 (Glutamine importer), CPT1A (Fatty acid metabolism), GLUT1 (Glucose importer), LDHA (Glycolysis), Citrate synthase and ATPA5 (Oxidative Phosphorylation). There was a higher RR of granulocytes (RR 2.1, CI 1.6-2.8, p<0.001) in EP compared to LP samples at the time of SMM diagnosis, but a lower RR of CD4 T cells (RR 0.40, CI 0.3-0.6, p< 0.001). Focusing on metabolic phenotypes of the PCs, we observed higher incidence RR of most metabolic markers: ASCT2 (RR=1.77; p=0.032), ATPA5 (RR=1.25; p<0.001), CPT1a (RR=2.42; p=0.015), and LDHA (RR 2.13; p<0.001) in EP compared to LP samples at the time of SMM diagnosis. However, GLUT1 had a lower incidence RR in EP patients (RR=0.79; p<0.001). The same modeling for non-PCs at the time of SMM diagnosis yielded higher expression of LDHA (RR=1.98; p<0.001) and ASCT2 (RR=3.3; p=0.002). Using the x and y coordinates and the corresponding phenotype classifications, we performed spatial statistical modeling based on spatial point processes to generate aggregated measures of how different types of cells of interest interacted. CD4 T cells were more isolated in LPs compared to EPs (p =0.046). Segregation indices for PCs and CD4 T cells indicated that they were more integrated/collocated in EPs. Granulocytes were more isolated in EPs although the difference was not as pronounced (p= 0.07). PCs were more integrated with granulocytes (p=0.06) and B cells (p=0.07) in LP patients. Further analyses of paired samples at the time of progression to MM will be reported at the time of the presentation. Conclusion This study is the first to provide whole-slide, single-cell, spatial proteomic characterization of clonal PCs and immune cells in the FFPE BMs of high-risk SMM patients with varying progression times to MM. Distinct metabolic pathway markers in clonal PCs and their spatial relationships with immune cell subsets are closely associated with the risk of progression to MM. These findings illuminate the complex interactions between the metabolic states of clonal PCs and their spatial orientation relative to immune cells in the pathogenesis of MM.
Differences in the proteome within extracellular vesicles between premalignant and malignant plasma cell disorders
Vanderboom, Patrick M. , Chawla, Yogesh , Dasari, Surendra , Kapoor, Isha , Kumar, Shaji , Nair, K. Sreekumaran , Gonsalves, Wilson I. , Kumar, Shaji K , Gonsalves, Wilson , Nair, K Sreekumaran , Chawla, Yogesh

Mayo Clinic

European Journal of Haematology | May 28, 2024 | Volume: 113 | Issue: 3 | Pages: 351-356

10.1111/ejh.14246 | PMID 38804098 Get It

AbstractBackgroundPrecursor plasma cell disorders such as monoclonal gammopathy of undetermined significance (MGUS) always precede the development of active malignancies such as multiple myeloma (MM). There is a need for novel biomarkers to identify those patients with such precursor plasma cell disorders who rapidly progress to MM. Plasma‐derived extracellular vesicles (EVs) may serve as a reservoir of potential biomarkers that can shed light on the pathogenesis and disease biology of MM.MethodsThis study isolated small EVs (SEVs) and large EVs (LEVs) from the platelet‐poor peripheral blood plasma of MGUS (n = 9) and MM (n = 12) patients using the size exclusion chromatography‐based method and evaluated their proteome using a label‐free proteomics workflow.ResultsIn total, 2055 proteins were identified in SEVs, while 2794 proteins were identified in LEVs. The transferrin receptor (or CD71) protein was upregulated in both populations of EVs derived from MM patients compared to MGUS patients and was of prognostic significance. Similarly, three isoforms of serum amyloid A (SAA) protein, SAA1, SAA2, and SAA4, were also highly upregulated in SEVs within MM patients relative to MGUS patients. Finally, CD40 expression was also higher in the LEVs derived from MM patients than in MGUS patients.ConclusionsThis study demonstrates the feasibility of successfully isolating both SEVs and LEVs from the peripheral blood of patients with plasma cell disorders and quantifying protein biomarkers within these EVs that could be of prognostic and diagnostic interest.
Levels of Individual Mid and Long Chain Polyunsaturated Triacylglycerols (TAGs) Are Different between the Bone Marrow Microenvironment of Patients with Multiple Myeloma (MM) and Monoclonal Gammopathy of Unknown Significance (MGUS)
Anderson, Emilie, Vasquez, Isas Rosario, Simon, Rachel A, Hitosugi, Taro , Kumar, Shaji Kunnathu, Chawla, Yogesh, Gonsalves, Wilson I.

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 4708-4708

10.1182/blood-2023-186983 Get It

Background: It has been recently demonstrated that altered lipid metabolism involving increased free fatty acids (FFAs) uptake supports the growth and proliferation of MM cells (Panaroni et al. Blood 2022; Farell et al. Elife 2023). Whether the availability of FFAs in the bone marrow (BM) microenvironment is associated with the pathogenesis of MM from MGUS has not been previously evaluated. Thus, we evaluated if individual species of FAs or FA-containing lipids such as triacylglycerols (TAGs), diacylglycerols (DAGs), and monoacylglycerols (MAGs) are differentially present between the BM microenvironment of MGUS and MM patients. Methods: Lipid profiles of BM plasma samples (reflective of the BM microenvironment) from patients with a spectrum of plasma cell disorders (22 MGUS and 24 MM (15 newly diagnosed and 9 relapsed/refractory)) were acquired by liquid chromatography (LC)/tandem mass spectrometry (MS), and individual lipid species were quantified based on single-point quantification using 55 isotopically labeled internal standards. Concentration-based lipid species data was analyzed by the web-based tool MetaboAnalyst 5.0. Data was normalized by quantile normalization, log transformed and scaled by Pareto scaling. p values <0.05 were considered significant. Results: A total of 993 distinct lipid species were quantified by the MS-based targeted lipidomics assessment. Of these lipid species, the levels of individual mid-chain (≤50 carbon chain length) and long-chain (≥52 carbon chain length) polyunsaturated TAGs were the most differentially present in the BM plasma of MM compared to MGUS patients (Figure 1A). Even though a principal component analysis (PCA) involving all lipid species showed moderate separation of MM from MGUS patients, five MGUS patients (categorized as MGUS-other (MGO)) who clustered more towards MM patients compared to the remaining MGUS patients had a distinct pattern of individual mid and long-chain polyunsaturated TAG levels that were comparable to MM patients (Figure 1B). Furthermore, the proliferation rate of clonal plasma cells in the BM of these MM and MGUS as measured by the S-phase% was found to be directly correlated with the level of long-chain polyunsaturated TAGs. Conclusions: Mid and long-chain polyunsaturated TAGs are present in lower and higher levels, respectively, in the BM microenvironment of MM compared to MGUS patients. These findings continue to support the importance of FA-containing TAGs and other lipids in the pathogenesis of MM. Future confirmatory studies evaluating the biological significance of these differences are required to determine if they can be exploited for diagnostic and therapeutic purposes.
Evaluating Differences in the Proteome Within Extracellular Vesicles Between Pre- Malignant and Malignant Plasma Cell Disorders
Vanderboom, Patrick M. , Dasari, Surendra , Kapoor, Isha , Kumar, Shaji , N., K., Chawla, Yogesh, N, K Sreekumaran, Gonsalves, Wilson I.

Mayo Clinic

No container title available | November 30, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3673796/v1 Get It

Abstract Background: Precursor plasma cell disorders such as monoclonal gammopathy of undetermined significance (MGUS) always precede the development of active malignancies such as multiple myeloma (MM). There is a need for novel biomarkers to identify those patients with such precursor plasma cell disorders who rapidly progress to MM. Plasma-derived extracellular vesicles (EVs) may serve as a reservoir of potential biomarkers that can shed light on the pathogenesis and disease biology in MM. Methods: This study isolated small EVs (SEVs) and large EVs (LEVs) from the platelet-poor peripheral blood plasma of MGUS (n=9) and MM (n=12) patients using the size exclusion chromatography (SEC)-based method and evaluated their proteome using a label-free proteomics workflow. Results: In total, 2,055 proteins were identified in SEVs, while 2,794 proteins were identified in LEVs. The transferrin receptor (TFRC or CD71) protein was upregulated in both populations of EVs derived from MM patients compared to MGUS patients and was of prognostic significance. Similarly, three isoforms of serum amyloid A (SAA) protein, SAA1, SAA2, and SAA4, were also highly upregulated in SEVs within MM patients relative to MGUS patients. Finally, CD40 expression was also higher within the LEVs derived from MM patients than MGUS patients. Conclusions: This study demonstrates the feasibility of successfully isolating both SEVs and LEVs from the peripheral blood of patients with plasma cell disorders and quantifying protein biomarkers within these EVs that could be of prognostic and diagnostic interest.
Sensitization of Tumor Cells to IFNy-Mediated Cell Death
Sun, N , Krogman, Erica N., Ting, Adrian T. , Chawla, Yogesh

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 245.22-245.22

10.4049/jimmunol.210.supp.245.22 Get It

Abstract There is increasing evidence that immunotherapies make tumor cells more vulnerable to the host’s own immune system that can lead to long-term and durable remission. To date, only a small percentage of cancer patients have benefited from this approach and advances in this field will likely come from a greater understanding of the interaction between immune cells and their tumor targets. T cells are critical to a successful anti-tumor response due to their ability to directly lyse tumor cells by releasing cytolytic granules, and to produce inflammatory cytokines, such as interferon gamma (IFNγ). IFNγ has several functions in an anti-tumor response. On the immune cell side, IFNγ is a major driver of Th1 differentiation that leads to the activation of T cells and NK cells. On the tumor side, IFNγ can enhance MHC class I presentation but also inhibitory receptors such as PD-1. However, it is not as clear whether IFNγ is directly cytotoxic for tumor cells. If that is the case, it is also likely that due to selection pressure exerted by T cells, tumor cells may have acquired mechanisms to protect themselves against this possibility. Thus, I hypothesized that tumor cells are normally resistant to killing by IFNγ but can be sensitized if the death protection mechanisms are disabled. In preliminary studies using the B16F1 murine melanoma model, we found that while wild-type (WT) melanoma cells were completely resistant, tumor cells with knockouts of two kinases (DKO) became highly sensitized to IFNγ-mediated apoptotic death. Furthermore, the DKO tumors were also more easily killed by T cells in an IFNγ-dependent manner. These findings will provide insight into potential targets for therapeutic intervention to enhance immune-mediated destruction of tumors.